# Electra Therapeutics Inc. (ETRA) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $8.07, market value $507 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Electra Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -12.1%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 204.4%**. A 204.4% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Growth
- **EPS growth (1 yr): -186.4%**. Earnings per share fell 186.4%.

## Financial health
- **Current ratio: 9.82** (quick 9.82). Current assets cover the next year's liabilities 9.82 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Electra Therapeutics Inc. does not currently pay a dividend, but it returned -18.1% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Electra Therapeutics Inc.; the consensus is strong_buy, with an average price target of $33.20 (+311% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -47.9%** (14.9% above the low). Trading 48% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 24**. An RSI of 24 is oversold; bounces are common, but oversold can stay oversold in a real decline.

Live score and charts: https://foliofundamentals.com/analyzer?s=ETRA · Page: https://foliofundamentals.com/stocks/etra

Not investment advice.